| First Author | Warrington RC | Year | 1989 |
| Journal | Br J Cancer | Volume | 60 |
| Issue | 5 | Pages | 652-6 |
| PubMed ID | 2803940 | Mgi Jnum | J:26027 |
| Mgi Id | MGI:73753 | Doi | 10.1038/bjc.1989.333 |
| Citation | Warrington RC, et al. (1989) L-histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia. Br J Cancer 60(5):652-6 |
| abstractText | DBA/2J mice bearing a clonal isolate of the transplantable murine lymphocytic leukaemia line P388 were used to examine the effects of L-histidinol on the antitumour activity of three alkalyating agents (bis-chloroethylnitrosourea (BCNU), cis-diamminedichloroplatinum (II) (cisDDP) and cyclophosphamide) and the antitumour antibiotic daunomycin. Single, combined treatments with L-histidinol and either BCNU or cisDDP, at doses of the alkylating agents which were ineffective when used alone, were completely curative. Dose-response studies showed that L-histidinol conferred dose-dependent, synergistic improvements on the capacities of both BCNU and cisDDP to increase the life-span of DBA/2J mice bearing P388 leukemia. For combinations of L-histidinol and cyclophosphamide or daunomycin, two successive treatments with L-histidinol and drug were required to obtain a significant portion of long-term survivors. Thus, in this model system, the L-histidinol/anticancer drug combination approach for improving experimental cancer chemotherapy can be employed successfully with three alkylating agents and the antitumour antibiotic daunomycin. |
